Veracyte Launches Test Identifying Breast Cancer Patients Who Don’t Need Chemo
The Prosigna test estimates the 10-year probability of distant breast cancer recurrence. It thus help guide treatment decisions, including predicting whether hi...
The Prosigna test estimates the 10-year probability of distant breast cancer recurrence. It thus help guide treatment decisions, including predicting whether high risk patients are likely to benefit from chemotherapy. The post Veracyte Launches Test Identifying Breast Cancer Patients Who Don’t Need Chemo appeared first on Inside Precision Medicine .